What is Celmatix?
Headquartered in the United States, Celmatix operates at the intersection of advanced biotechnology and female reproductive health. The firm is dedicated to the discovery and development of novel therapeutics that address significant unmet medical needs, including endometriosis, Polycystic Ovary Syndrome (PCOS), and ovarian folliculogenesis. Their product portfolio is distinguished by a first-in-class oral FSH receptor agonist and innovative JNK inhibitors, positioning the company as a leader in precision medicine for women. By leveraging deep insights into female biology, Celmatix is effectively bridging the gap between traditional fertility care and modern pharmaceutical intervention, creating a scalable model for long-term therapeutic impact.
How much funding has Celmatix raised?
Celmatix has raised a total of $54.1M across 9 funding rounds:
Private Equity
$806K
Series A
$1.5M
Private Equity
$4M
Private Equity
$5.5M
Private Equity
$3.8M
Private Equity
$4.8M
Private Equity
$21M
Other Financing Round
$12.5M
Private Equity (2011): $806K, investors not publicly disclosed
Series A (2012): $1.5M supported by Topspin Partners
Private Equity (2013): $4M, investors not publicly disclosed
Private Equity (2014): $5.5M, investors not publicly disclosed
Private Equity (2015): $3.8M, investors not publicly disclosed
Private Equity (2016): $4.8M, investors not publicly disclosed
Private Equity (2016): $21M supported by Topspin Partners
Other Financing Round (2017): $12.5M featuring Topspin Partners
Key Investors in Celmatix
Topspin Partners
Topspin Consumer Partners is a private equity firm dedicated to growing branded consumer products and services companies. They partner with founder-owners and executive teams to facilitate company growth through strategic guidance, operational improvements, and capital access.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Celmatix?
With the support of its recent capital injection, Celmatix is poised to accelerate its clinical trial milestones and expand its therapeutic reach. The strategic focus remains on advancing its lead candidates through the regulatory pipeline while maintaining a robust research engine. As the company scales, it is expected to leverage its existing intellectual property to forge new partnerships, potentially disrupting the current standard of care for chronic reproductive conditions. The firm's ability to maintain consistent growth trajectories suggests a long-term commitment to transforming the landscape of women's health through high-impact, science-driven solutions.
See full Celmatix company page
